Aktienanalyse zu Alps Group Inc (ALPS)ALPSAlps Group Inc

Alps Group Inc is the parent company of Alps Life Sciences Inc., an integrated biotechnology platform integrating research and development, medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally. The Company has cultivated a diverse pipeline covering various biotechnology research areas. This includes initiatives focused on MyImmune (NK cells), CAR-T cells, COVID-19 mRNA vaccine, diabetes therapeutics, and advancements in stem cell technologies such as induced Pluripotent Stem Cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technology. The Company provides aesthetic treatments, cosmetic procedures, general healthcare and wellness services. The Company’s aesthetic services and cosmetic surgery services include non-surgical aesthetic services and surgical aesthetic services. It operates a molecular laboratory and a cGMP cell and gene therapy research and cultivation laboratory. It operates in the Healthcare sector.

Alps Global Holding Pubco is not a good buy right now due to significant financial losses and compliance issues. The current price is $0.38, and the company has reported a staggering 85.64% decline over the past year. Additionally, the negative net income for the last quarter was $893,896, indicating ongoing financial struggles. The main risk is the Nasdaq compliance notice, which requires the stock to regain a minimum bid price of $1.00 by November 11, 2026, or face potential delisting.